| International Session（Symposium）6(JSGE・JGES・JSGS・JSGCS) |
| Fri. November 6th 9:00 - 12:00 Room 11: Portopia Hotel South Wing Topaz |
| EUS-guided injection of virus and dendritic cells (DCs) in the treatment of pancreatic cancer | |||
| Yoshiki Hirooka1, Senju Hashimoto1, Ryoji Miyahara1 | |||
| 1Department of Gastroenterology and Gastroenterological Oncology, Fujita Health University | |||
|
|||
|
|||
| Background and Methods: HF10 spontaneously mutated oncolytic virus derived from a herpes simplex virus-1 (study-1) and zoledronate (Zol) stimulated DCs were injected into the pancreatic cancer (study-2) under EUS-guidance in combination with chemotherapy. Results of two studies are presented. Result and Conclusions: (Study-1): Twelve patients enrolled in this clinical trial, and ten subjects received this therapy. Five patients showed Grade III myelosuppression and two patients developed serious adverse events (AEs) (perforation of duodenum, hepatic dysfunction). However, all of these events were judged as AEs unrelated to HF10. Tumor responses were three partial responses (PR), four stable diseases (SD), and two progressive diseases (PD) out of nine subjects who completed the treatment. Target lesion responses were three PRs and six SDs. The median progression free survival (PFS) was 6. 3 months, whereas the median OS was 15.5 months. Two subjects from Cohort 1 and 2 showed downstaging and finally achieved surgical complete response (CR). (Study-2): Seven of 15 patients showed a stable disease (SD) and most of the patients showed long-term clinical responses. By using appropriate and precise biomarkers, such as NLR and CD8+/Treg ratio, the present comprehensive immunotherapy could be more beneficial for patients with pancreatic carcinoma. |
|||
|
Index Term 1: Virus injection therapy Index Term 2: immature DC injection therapy |
|||
| Page Top | |||